About Syntimmune
Syntimmune is a company based in New York (United States) founded in 2013 was acquired by Alexion in September 2018.. Syntimmune has raised $78 million across 5 funding rounds from investors including Alexion, Baxalta and Apple Tree Partners. Syntimmune operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Syntimmune
Syntimmune has successfully raised a total of $78M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $50.0M
-
First Round
First Round
(01 Jun 2013)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2017 | Amount | Series B - Syntimmune | Valuation | Apple Tree Partners |
|
| Nov, 2016 | Amount | Series A - Syntimmune | Valuation | Apple Tree Partners | |
| Mar, 2016 | Amount | Series A - Syntimmune | Valuation | Apple Tree Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Syntimmune
Syntimmune has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, Baxalta and Apple Tree Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Founded Year | Domain | Location | |
|
Developer of therapies for orphan diseases and other disease conditions
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Syntimmune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Syntimmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Syntimmune Comparisons
Competitors of Syntimmune
Syntimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Syntimmune
Frequently Asked Questions about Syntimmune
When was Syntimmune founded?
Syntimmune was founded in 2013.
Where is Syntimmune located?
Syntimmune is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Syntimmune a funded company?
Syntimmune is a funded company, having raised a total of $78M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 01, 2013.
What does Syntimmune do?
The company was founded in 2013 in New York, United States, within the biotechnology sector. Neonatal Fc receptor (FcRn) biology is investigated as a target for IgG-mediated autoimmune diseases. The lead program, SYNT001, consists of a biologic designed to block the FcRn-IgG interaction and is undergoing IND-enabling studies for one such disease. Two further programs addressing distinct elements of FcRn biology are under development.
Who are the top competitors of Syntimmune?
Who are Syntimmune's investors?
Syntimmune has 4 investors. Key investors include Alexion, Baxalta, Apple Tree Partners, and Partners HealthCare.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.